In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: June 2025
OCRA Featured in Fortune Article on Surgery That Reduces Ovarian Cancer Risk Ovarian Cancer Research Alliance’s (OCRA) leadership in raising awareness about opportunistic salpingectomy—a simple procedure that can significantly reduce … Continued
OCRA’s Advocate’s Corner: June 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget Update: Critical Cancer Programs at Risk Congress is deep into its work on the fiscal year 2026 … Continued
OCRA Featured in Fortune on Surgery That Reduces Ovarian Cancer Risk
A Fortune article published on June 16, 2025, titled I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know … Continued